Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
P/B ratio for Deciphera Pharmaceuticals, Inc. (DCPH)
P/B ratio as of 2023: 3.91
According to Deciphera Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.91. At the end of 2022 the company had a P/B ratio of 3.62.
P/B ratio history for Deciphera Pharmaceuticals, Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.91 |
| 2022 | 3.62 |
| 2021 | 1.86 |
| 2020 | 5.86 |
| 2019 | 4.88 |
| 2018 | 2.65 |
| 2017 | 2.07 |
| 2016 | -2.64 |
| 2015 | -3.20 |